4/A: Sensei Biotherapeutics: Insider Transaction Update

Anand Kiran Parikh, President and CEO of Sensei Biotherapeutics, Inc., has filed an amendment to a Form 4 detailing transactions related to a merger and stock options.

Summary

• This filing is an amendment to a previously filed Form 4 by Anand Kiran Parikh, President and CEO of Sensei Biotherapeutics, Inc. (FTH).
• The amendment corrects previously reported information regarding stock options and Series B Preferred Stock.
• The transactions are related to a merger agreement dated February 17, 2026, involving Sensei Biotherapeutics, Inc., Sapphire First Merger Sub, Inc., Sapphire Second Merger Sub, LLC, Faeth Holdings Therapeutics, Inc. (HoldCo), and Faeth Therapeutics, LLC.
• Anand Kiran Parikh received 761,428 shares of Series B Convertible Preferred Stock in exchange for 4,062,777 shares of Faeth Holdings Therapeutics, Inc. common stock.
• These Series B Preferred Stock shares are convertible into 761,428,000 shares of Sensei Biotherapeutics' Common Stock (1,000 shares of Common Stock per share of Series B Preferred Stock).
• The filing also details adjustments to employee stock options received in exchange for Faeth common stock options, with specific exercise prices and vesting schedules mentioned.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative correction of a previous disclosure without new financial or strategic information.

Positives

• The amendment clarifies and corrects previously reported data, ensuring accuracy in beneficial ownership disclosures.
• The Series B Preferred Stock received is convertible into a significant number of common shares, indicating potential future upside.
• The reporting person holds a directorship and an officer position (President and CEO), aligning their interests with the company.

Negatives

• The filing is an amendment, suggesting initial inaccuracies in reporting, which could raise minor concerns about internal controls.
• The details provided are primarily transactional and do not offer insights into the company's operational performance or future prospects.

Risks

• Potential for further inaccuracies in reporting or disclosures, although this amendment aims to rectify past issues.
• The conversion of preferred stock to common stock is subject to the terms and conditions outlined in the Certificate of Designation, which may have specific limitations or requirements.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance. It focuses solely on reporting ownership changes and transactions.

Management Comments

• This amendment corrects the previously reported transactions on Form 4 filed February 19, 2026, to disclose the correct number of shares included in the option awards and the correct number of shares of Series B Preferred Stock.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for insider transactions and are crucial for understanding executive and director involvement with company stock. The merger-related transactions indicate corporate restructuring or strategic partnerships within the biotherapeutics sector, a field characterized by significant M&A activity and complex financing structures.

Related Party Transactions

• The transactions described involve the reporting person, Anand Kiran Parikh, in his capacity as President and CEO, and are related to a merger involving entities connected to the company and its operations.

Stakeholder Impact

• Shareholders: The conversion of Series B Preferred Stock could lead to an increase in the number of outstanding common shares, potentially impacting earnings per share if not accompanied by proportional profit growth. The accuracy of reporting is vital for shareholder confidence.
• Employees: The filing details adjustments to stock options, which are a form of employee compensation and incentive. Clarity on these awards is important for employee morale and retention.
• Management: The reporting person's direct involvement in these transactions and their roles as Director and CEO highlight their significant stake and influence within the company.

Next Steps

• The Series B Preferred Stock is convertible into Common Stock, subject to the terms of its designation.
• Vesting schedules for employee stock options continue as per the outlined terms.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Sensei Biotherapeutics, FTH, Anand Kiran Parikh, Merger Agreement, Series B Preferred Stock, Stock Options, Beneficial Ownership, Convertible Stock